Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

The merits of new alternatives to the Papanicolaou test

Erin Ellison
CMAJ September 18, 2001 165 (6) 739;
Erin Ellison
Histocytopathologist Laboratory Medicine Program Lakeridge Health Corporation Oshawa, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The claim by Eduardo Franco and colleagues that “nearly half of specimens [cervical smears] yield false-negative results” is misleading, as are several of their claims regarding the value of liquid-based and automated cytology.1 Most studies quote a false- negative rate of approximately 1–5%.2,3,4 Any laboratory with a 50% false- negative rate would be shut down.

Liquid-based preparations are not free of drawbacks, including the loss of necroinflammatory background that can be a clue to malignancy. Although it is true that “virtually all cellular material is made available to the laboratory,” only a small proportion of this material is placed on the slide for screening. Conventional preparations contain many more cells. The newer methodologies are also very expensive and tightly controlled by a few companies, drawbacks that are not just “perceived.” Their claims of improved false-negative rates are questioned by a recent meta-analysis, which concluded that most of the studies of liquid-based preparations and automation were “severely limited by design, inadequate reference standards, and incomplete verification of cytological diagnoses.”5 Finally, none of these technologies will reduce the number of false-negative cases that are due to suboptimal sampling or interval disease progression.

If the jury is still out on the statistical value of these methodologies, the societal value is even less certain. Traditional cervical smears have been successful because they are inexpensive, easy to perform and generally accurate. Because of slow progression to malignancy, yearly smears will detect almost all serious disease even if it is missed on one specimen. The greatest gain in cervical cancer control is in first-time screening, and the increase in cost associated with new techniques will reduce access by underserved populations. Increased costs will also follow the inevitable rise in false-positive tests.

There is a social cost in quoting questionable statistics about false- negative cervical smears, eroding both patients' and clinicians' confidence in a test that is fundamentally sound. Calculated from 8 representative studies,3 the predictive value of a negative smear for significant disease is 99.96%. It's hard to improve on that.

References

  1. 1.↵
    Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001; 164(7):1017-25.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Lemay C, Meisels A. 100% Rapid (partial) rescreening for quality assurance. Acta Cytol 1999; 43: 86-8.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Arbyn M, Schenck U. Detection of false negative Pap smears by rapid reviewing, a metaanalysis. Acta Cytol 2000;44:949-57.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Appendix A. False negative and false negative rates (FNRS): a review. In: Regulatory closure of cervical cytology laboratories. Recommendations for a public health response. MMWR 1997; 46(RR17):16-8.
    OpenUrl
  5. 5.↵
    Broadstock M. Effectiveness and costs effectiveness of automated and semi-automated cervical screening devices: a systematic review. NZTA Rep 3(1). Christchurch (N.Z.): New Zealand Health Technology Assessment Clearing House; 2000.
PreviousNext
Back to top

In this issue

CMAJ
Vol. 165, Issue 6
18 Sep 2001
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The merits of new alternatives to the Papanicolaou test
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The merits of new alternatives to the Papanicolaou test
Erin Ellison
CMAJ Sep 2001, 165 (6) 739;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
The merits of new alternatives to the Papanicolaou test
Erin Ellison
CMAJ Sep 2001, 165 (6) 739;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The 5 Ps need an update: toward a comprehensive sexual history
  • Don’t ignore perimenopause
  • Hospital-at-home programs in Canada: challenges and pitfalls
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire